Absci (ABSI) H.C. Wainwright 28th Annual Global Investment Conference summary

Platform and strategy

• Transitioned from platform partnerships to a clinical-stage focus with three programs and a wholly owned prolactin receptor franchise.

• Vision centers on developing direct-to-consumer (DTC) therapeutics, leveraging telemedicine for broader patient access.

• Proprietary AI-driven Atlas and Origin platforms accelerate target discovery, antibody design, and program development.

• Business model now prioritizes internal program advancement, with selective partnership opportunities based on asset merit.

• Strategic investment from Eli Lilly ($40M of $100M total) provides advisory input without encumbering program rights.

Clinical pipeline and milestones

• Lead asset ABS-201, an AI-designed anti-prolactin receptor antibody, targets pattern hair loss and endometriosis.

• June interim phase I data showed no serious adverse events and a 65-day half-life, supporting convenient dosing.

• 13-week proof-of-concept readout expected December, with full 26-week data in early 2025; endometriosis phase II to start Q4 2024.

• Durability and regenerative mechanism to be assessed via long-term follow-up and open-label extension studies.

• Label expanded from androgenetic alopecia to pattern hair loss, broadening U.S. addressable market to 80 million.

Platform capabilities and differentiation

• Atlas integrates omics, genetics, and literature data to identify novel targets and indications, feeding into Origin for antibody design.

• Platform enables IND-enabling studies in under 2.5 years and under $15M, with ongoing efforts to further reduce time and cost.

• AI-driven workflow compresses timelines and enhances quality, with Atlas and Origin used primarily for internal programs.

• Platform validated by clinical progress and external partnerships, with ABS-202 emerging from Atlas-driven discovery.